READ-ONLY DIGITIZATION RESULT
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.
Blood Adv · 2024-Oct-22 · PMID 38968156
Panel C质量警告待 EXE 对齐验证
OS
Figure 5. Comparison of PFS, EFS, and OS between the nilotinib arm and the dasatinib arm. PFS (A), EFS (B), and OS (C). PFS, EFS, and OS were defined as the interval from the date of randomization until the date of progression or death from any causes, whichever came first (PFS); until the date of the earliest of defined events (EFS); and until the date of death from any causes (OS), respectively. PFS, EFS, and OS were analysis on the ITT population using the Kaplan-Meier method with a log-rank test.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T18:45:19+00:00 |